Эрибулин – новый микротрубочковый ингибитор для лечения метастатического рака молочной железы


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Согласно современным рекомендациям, не существует какого-либо единого стандарта лечения пациенток с метастатическим раком молочной железы (РМЖ), ранее получавших терапию. Эрибулина мезилат недавно был одобрен в России для лечения больных местно-распространенным или метастатическим РМЖ, у которых прогрессирование наступило после применения двух и более режимов химиотерапии, назначенной по поводу распространенного заболевания и включавшей антрациклины и таксаны. Благодаря уникальному механизму действия эрибулин, возможно, обладает более высокой, чем другие ингибиторы микротрубочек, противоопухолевой активностью, а также потенциалом преодоления химиорезистентности, являющейся существенной клинической проблемой. Одобрение эрибулина Европейским агентством по лекарственным средствам в 2011 г. было основано на результатах исследования III фазы EMBRACE - первого исследования, в котором было продемонстрировано значительное увеличение выживаемости больных распространенным РМЖ, ранее получавших антрациклины и таксаны. Кроме того, данные, полученные в исследовании 301, подтверждают целесообразность применения эрибулина для женщин с меньшим стажем лечения, чем для участников исследования EMBRACE. Результаты субанализов данных, полученных в этих исследованиях, также указывают на то, что в отдельных группах пациенток, в т. ч. при тройном отрицательном фенотипе, имеющих тройной отрицательный фенотип опухоли, влияние эрибулина на общую выживаемость может быть более выраженным, чем в общей популяции пациенток. Наряду с преимуществами в эффективности эрибулин обладает хорошей переносимостью, клинически приемлемым и контролируемым профилем побочных эффектов. В данном обзоре приводится описание эрибулина, включая его механизм действия и ключевые данные об эффективности и безопасности, полученные в исследованиях III фазы.

Полный текст

Доступ закрыт

Об авторах

М. Б Стенина

ФГБУ «РОНЦ им. Н.Н. Блохина» РАМН

Email: mstenina@mail.ru
д.м.н, ведущий научный сотрудник отделения клинической фармакологии и химиотерапии

Список литературы

  1. Cardoso F, Harbeck N, et al. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl. 7):11–9.
  2. Состояние онкологической помощи населению России в 2012 году / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петро-вой. М., 2013. 231 с.
  3. Morris PG. Advances in therapy: eribulin improves survival for metastatic breast cancer. Anti-cancer Drugs 2010;21:885–89.
  4. Chia SK, Speers CH, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007;110:973–79.
  5. Rivera E. Management of metastatic breast cancer. Am J Clin Oncol 2010;33:176–85.
  6. Murphy CG, Seidman AD. Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes. Clin Breast Cancer. 2009;9(Suppl. 2):58–65.
  7. Gonzalez-Angulo AM, Morales-Vasquez F, et al. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007;608:1–22.
  8. European Medicines Agency. Tyverb summary of product characteristics. 2013.
  9. European Medicines Agency. Perjeta summary of product characteristics. 2013.
  10. Genetech. Kadcyla prescribing information. 2013.
  11. European Medicines Agency. Abraxane summary of product characteristics. 2013.
  12. Gradishar WJ. The place for eribulin in the treatment of metastatic breast cancer. Curr Oncol Rep 2011;13:11-6.
  13. Engebraten O, Moen Vollan HK, et al. Triplenegative breast cancer and the need for new therapeutic targets. Am J Pathol 2013;Aug 3 [epub ahead of print].
  14. Guarneri V, Dieci MV, et al. Relapsed triple-negative breast cancer: challenges and treatment strategies. Drugs 2013;11[epub ahead of print].
  15. Cortes J, O'Shaughnessy J, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study. Lancet 2011;377:914-23.
  16. Beusterien K, Grinspan T, et al. Patient preferences for chemotherapies used in breast cancer. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2011; Chicago, IL, USA. Abstract e19667.
  17. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology - Breast Cancer. Version 3 [online] 2013. Available from: http://www.nccn.org/professionals/physi-cian_gls/f_guidelines.asp#breast [last accessed August 2013].
  18. Donoghue M, Lemery S, et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a «physician's choice» control arm in a randomised approved trial. Clinical Cancer Research 2012;18:1496-505.
  19. European Medicines Agency. Halaven (eribulin) [online]. 2013. Available from: http://www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/medi-cines/002084/human_med_001427. jsp&mid=WC0b01ac058001d124 [Last accessed August 2013].
  20. Hirata Y, Uemura D. Halichondrins antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986;58:701-10.
  21. Kuznetsov G, Towle MJ, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004;64:5760-66.
  22. Towle MJ, Salvato KA, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61:1013-21.
  23. Jordan MA, Kamath K, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer The. 2005;4:1086-95.
  24. Okouneva T, Azarenko O, et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008;7:2003-11.
  25. Smith JA, Wilson L, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010;49:1331-37.
  26. Towle MJ, Salvato KA, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 2011;71:496-505.
  27. Kuznetsov G, TenDyke K, et al. Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. Presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, October 22-26, 2007; San Francisco, CA, USA. Abstract C58.
  28. Agoulnik SI, Oestreicher JL, et al. Eribulin and paclitaxel differentially affect gene expression profiling of blood vessel cells and in vitro angiogenesis in co-cultures of human endothelial cells with pericytes. Presented at the American Association for Cancer Research (AACR) Annual Meeting, April 6-10, 2013; Washington, DC, USA. Abstract 3830.
  29. McCracken PJ, Ito K, et al. Eribulin mesylate alters vascular function in human triple-negative (TN) breast MX-1 and MDA-MB-231 tumor xenograft models as measured by DCE-MRI. Presented at the American Association for Cancer Research (AACR) Annual Meeting, April 6-10, 2013; Washington, DC, USA. Abstract 4502.
  30. Matsui J, Toyama O, et al. Eribulin caused remodeling of tumor vasculature altering gene expression profiling in angiogenesis and epithelial-mesenchymal transition (EMT) signaling pathway of host normal cells within human breast cancer cell (BCC) xenografts in nude mice. Presented at the American Association for Cancer Research (AACR) Annual Meeting, April 6-10, 2013; Washington, DC, USA. Abstract 1413.
  31. Goel S, Mita AC, et al. A Phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009;15:4207-12.
  32. Tan AR, Rubin EH, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009;15:4213-19.
  33. Synold TW, Morgan RJ, et al. A Phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial. J Clin Oncol 2005;23(Suppl. 16):3036.
  34. Minami H, Mukoharaz T, et al. A Phase I study of eribulin mesylate (E7389) in patients with refractory cancers. Eur J Cancer 2008;6(Suppl.):140 (abstract 446).
  35. Vahdat LT, Pruitt B, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009;27:2954-61.
  36. Cortes J, Vahdat L, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28:3922-28.
  37. Twelves C, Loesch D, et al. Updated survival analysis of a Phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in subjects with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8-12, 2010;an Antonio, TX, USA. P6-14-8.
  38. Twelves C, Vahdat L, et al. Survival outcomes for eribulin in metastatic breast cancer are independent of age. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2011;Chicago, IL, USA. Poster 1060.
  39. Twelves C, Akerele C, et al. Eribulin mesylate (E7389) vs treatment of physician's choice (TPC) in patiehts (pts) with metastatic breast cancer (MBC): subgroup analyses from the EMBRACE study. Ann Oncol 2010;21(Suppl. 8): Abstract 2750.
  40. Cortes J, Twelves CL, et al. Clinical response to eribulin in patients with metastatic breast cancer is independent of time to first metastatic event. Presented at the 1st Advance Breast Cancer International Consensus Conference (ABC1), November 3-5,2011;Lisbon,Portugal.Poster P0107.
  41. Blum JL, Twelves CJ, Dutcus C, et al. Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or MBC treated with eribulin mesylate: results from the Phase III EMBRACE study. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8-12, 2010; San Antonio, TX. USA. P6-13-01.
  42. US Food and Drug Administration. Eribulin mesylate [online]. 2010. Available from: http:// www.fda.gov/AboutFDA/CentersOffices/ OfficeofMedicalProductsandTobacco/ CDER/ucm234527.htm [Last accessed August 2013].
  43. Kaufman PA, Awada A, et al. A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Presented at the 35th San Antonio Breast Cancer Symposium (SABCS), December 4-8, 2012; San Antonio, TX, USA. Presentation S6-6.
  44. European Medicines Agency. Xeloda summary of product characteristics. 2013.
  45. Kaufman PA, Cortes J, et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 -June 4, 2013; Chicago, IL, USA. Poster 1049.
  46. Cortes J, Awada A, et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a Phase III, open-label, randomized study. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 31-June 4, 2013; Chicago, IL, USA. Abstract 1050.
  47. Vahdat LT, Garcia AA, et al. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat 2013;140(2):341-51.
  48. European Medicines Agency. Questions and answers on the withdrawal of the marketing authorisation for Ixempra [online]. 2009. Available from: http://www.ema.europa.eu/ docs/en_GB/document_library/Medicine_ QA/2010/01/WC500062428.pdf [last accessed August 2013].
  49. Bristol-Myers Squibb. Ixempra prescribing information. 2011.
  50. Saji S. Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane. BioDrugs. 2013;May 9 [epub ahead of print].

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2013

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах